Kura Oncology Files 8-K: Other Events
Ticker: KURA · Form: 8-K · Filed: Dec 2, 2025 · CIK: 1422143
| Field | Detail |
|---|---|
| Company | Kura Oncology, INC. (KURA) |
| Form Type | 8-K |
| Filed Date | Dec 2, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $135 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, other-events
Related Tickers: KURA
TL;DR
Kura Oncology filed an 8-K for 'Other Events' on Dec 2, 2025. Details TBD.
AI Summary
Kura Oncology, Inc. filed an 8-K on December 2, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these events, dollar amounts, or other named entities beyond the company itself.
Why It Matters
This filing indicates that Kura Oncology has reported significant events to the SEC, but the lack of detail requires further investigation to understand the implications for the company.
Risk Assessment
Risk Level: medium — The filing is for 'Other Events' without specific details, creating uncertainty about potential impacts on the company.
Key Players & Entities
- Kura Oncology, Inc. (company) — Registrant
- December 2, 2025 (date) — Date of earliest event reported
- 4930 Directors Place, Suite 500, San Diego, CA 92121 (address) — Principal Executive Offices
FAQ
What specific events are being reported by Kura Oncology, Inc. in this 8-K filing?
The filing is categorized under 'Other Events' and does not provide specific details about the nature of these events.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on December 2, 2025.
What is the principal executive office address for Kura Oncology, Inc.?
The principal executive office is located at 4930 Directors Place, Suite 500, San Diego, CA 92121.
What is the Commission File Number for Kura Oncology, Inc.?
The Commission File Number for Kura Oncology, Inc. is 001-37620.
What is the IRS Employer Identification Number for Kura Oncology, Inc.?
The IRS Employer Identification Number for Kura Oncology, Inc. is 61-1547851.
Filing Stats: 757 words · 3 min read · ~3 pages · Grade level 13.1 · Accepted 2025-12-02 08:10:16
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share KURA The Nasdaq Global Se
- $135 million — owa Kirin "), this milestone triggers a $135 million payment from Kyowa Kirin to the Company
Filing Documents
- d75668d8k.htm (8-K) — 25KB
- 0001193125-25-304559.txt ( ) — 136KB
- kura-20251202.xsd (EX-101.SCH) — 3KB
- kura-20251202_lab.xml (EX-101.LAB) — 18KB
- kura-20251202_pre.xml (EX-101.PRE) — 11KB
- d75668d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements Any forward-looking statements in this Current Report on Form 8-K are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to Kyowa Kirin's ability to make the expected milestone payment, including on the anticipated timing; risks associated with the commercialization of KOMZIFTI; the risk that the collaboration with Kyowa Kirin is unsuccessful; and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs, as well as those risks and uncertainties set forth more fully under the caption "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025 filed with the Securities and Exchange Commission ("SEC") on November 4, 2025, as well as discussions of potential risks, uncertainties and other important factors in the Company's other filings and reports with the SEC. All forward-looking statements contained in this Current Report on Form 8-K speak onl
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Kura Oncology, Inc. Date: December 2, 2025 By: /s/ Teresa Bair Teresa Bair Chief Legal Officer